Contact Us <\/i><\/a><\/div>\n[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|off|off” module_id=”ams-breadcrumb-section” _builder_version=”4.22.2″ _module_preset=”default” background_color=”rgba(255,255,255,0.9)” custom_margin=”-3.5rem||0px||false|false” custom_padding=”1rem||1rem||false|false” custom_padding_tablet=”1rem||1rem||true|false” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.18.1″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_sidebar area=”et_pb_widget_area_1″ module_id=”breadcrumbs” _builder_version=”4.18.1″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.21.0″ _module_preset=”default” custom_margin=”0px||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n
Terms of Reference<\/h5>\n
[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n
1. Membership<\/h5>\n
1.1. The Committee shall comprise at least two members all of whom shall be independent Non\u2010Executive Directors, at least one of whom shall have recent and relevant financial experience and the Committee as a whole shall have competence relevant in which the Company operates. The chair of the Board shall not be a member of the Committee. <\/pee> 1.2. Members of the Committee shall be appointed by the Board, on the recommendation of the Nomination Committee in consultation with the Chair of the Audit Committee. Only members of the Committee have the right to participate in the Committee meetings. However, the external auditor, internal auditor, Chief Financial Officer and Chief Executive Officer will be invited to attend meetings of the Committee on a regular basis and other individuals may be invited to attend and participate all or part of any meeting as and when appropriate. <\/pee> 1.3. Appointments shall for a period of up to three years which may be extended for up to two three-year periods, provided members continue to be independent. <\/pee> 1.4. The Board shall appoint the Committee Chair. In the absence of the Committee Chair and\/or an appointed deputy at a Committee meeting, the remaining members present shall elect one of themselves to Chair the meeting.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 2. Secretary<\/h5>\n
2.1. The Company Secretary or the Company Secretary, or their nominee, shall act as secretary of the Committee and will ensure that the Committee receives information and papers in a timely manner to enable full and proper consideration to be given to issues.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 3. Quorum<\/h5>\n
3.1. The quorum necessary for the transaction of business shall be two members of the Committee. <\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 4. Frequency of Meetings<\/h5>\n
4.1. The Committee shall meet at least three times a year at appropriate intervals in the financial reporting and audit cycle and otherwise as required.<\/pee> 4.2. Outside of the formal meeting programme, the Committee Chair will maintain a dialogue with key individuals involved in the Company\u2019s governance, including the Board Chair, the Chief Executive Officer, the Chief Financial Officer, the external audit lead partner and the internal audit lead partner.\t\t<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 5. Notice of Meetings<\/h5>\n
5.1. Meetings of the Committee shall be convened by the secretary of the Committee at the request of the Committee Chair or any of its members or at the request of external or internal auditor\u2019s if they consider it necessary.<\/pee> 5.2. Unless otherwise agreed, notice of each meeting confirming the venue, time and date together with an agenda of items to be discussed, shall be forwarded to each member of the Committee and any other person required to attend no later than three days before the date of the meeting. Supporting papers shall be sent to Committee members and to other attendees, as appropriate, at the same time.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 6. Minutes of Meetings<\/h5>\n
6.1. The secretary shall minute the proceedings and decisions of all Committee meetings, including a record of the names of those present and in attendance.<\/pee> 6.2. Draft minutes of Committee meetings shall be circulated to all members of the Committee. Once approved, minutes should be circulated to all other members of the Board unless, exceptionally, it would be inappropriate to do so.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 7. Engagement with Shareholders<\/h5>\n
7.1. The Committee Chair should attend the Annual General Meeting to answer any shareholder questions on the Committee\u2019s activities. In addition the Committee Chair should seek engagement with shareholders on significant matters related to the Committee\u2019s areas of responsibility.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 8. Duties<\/h5>\n
The Committee should have oversight of the Group as a whole and, unless required otherwise by regulation, carry out the duties below for the parent company, major subsidiary undertakings and the Group as a whole, as appropriate.<\/pee> 8.1. Financial Reporting<\/pee> 8.1.1. The Committee shall monitor the integrity of the financial statements of the Company, including its annual and half-yearly reports, preliminary announcements and any other formal statements relating to its financial performance, and review and report to the Board on significant financial reporting issues and judgements which those statements contain having regard to matters communicated to it by the auditor. <\/pee> 8.1.2. In particular, the Committee shall review and challenge as necessary:<\/pee> 8.1.2.1. the application of significant accounting policies and any changes to them;<\/pee> 8.1.2.2. the methods used to account for significant or unusual transactions where different approaches are possible;<\/pee> 8.1.2.3. whether the Company has adopted appropriate accounting policies and made appropriate estimates and judgements, taking into account the external auditor\u2019s views on the financial statements;<\/pee> 8.1.2.4. the clarity and completeness of disclosures in the financial statements and the context in which statements are made; and<\/pee> 8.1.2.5. all material information presented with the financial statements, including the Strategic Report and Corporate Governance statements relating to audit and risk management.<\/pee> 8.1.3 The Committee shall review any other statements requiring Board approval which contain financial information first, where to carry out a review prior to Board approval would be practicable and consistent with any prompt reporting requirements under any law or regulation including the Listing Rules, Prospectus Rules and Disclosure Guidance and Transparency Rules sourcebook.<\/pee> 8.1.4 When the Committee is not satisfied with any aspect of the proposed financial reporting by the Company, it shall report its views to the Board.<\/pee> 8.2. Narrative reporting<\/pee> Where requested by the Board, the Committee should review the content of the Annual Report and accounts and advise the Board on whether, taken as a whole, it is fair, balanced and understandable and provides the information necessary for shareholders to assess the Company\u2019s performance, business model and strategy and whether it informs the Board\u2019s statement in the Annual Report on these matters that is required under the 2018 UK Corporate Governance Code (\u201cCode\u201d).<\/pee> 8.3. Internal Controls and Risk Management Systems<\/pee> The Committee shall:<\/pee> 8.3.1. keep under review the effectiveness of the financial controls systems that identify, assess, manage and monitor financial risks, and other internal control and risk management systems; and<\/pee> 8.3.2. review and approve the statements to be included in the Annual Report concerning internal controls and, risk management, including the assessment of principal risks and emerging risks.<\/pee> 8.4. Compliance, Speaking-Up and Fraud<\/pee> The Committee shall:<\/pee> 8.4.1. review the adequacy and security of the Company\u2019s arrangements for its employees, contractors and external parties to raise concerns, in confidence, about possible wrongdoing in financial reporting or other matters. The Committee shall ensure that these arrangements allow proportionate and independent investigation of such matters and appropriate follow up action;<\/pee> 8.4.2. review the Company\u2019s procedures for detecting fraud; and<\/pee> 8.4.3. review the Company\u2019s systems and controls for the prevention of bribery and receive reports on non\u2010compliance.<\/pee> 8.5. Internal Audit<\/pee> The Committee shall:<\/pee> 8.5.1. approve the appointment or termination of appointment of the internal auditor;<\/pee> 8.5.2. review and approve the role and mandate of the internal audit, monitor and review the effectiveness of its work, and annually approve the internal audit charter ensuring it is appropriate for the current needs of the organisation;<\/pee> 8.5.3. review and approve the annual internal audit plan to ensure it is aligned to the key risks of the business, and receive regular reports on work carried out;<\/pee> 8.5.4. ensure internal audit has unrestricted scope, the necessary resources and access to information to enable it to fulfil its mandate, ensure there is open communication between different functions and that the internal audit function evaluates the effectiveness of these functions as part of its internal audit plan, and ensure that the internal audit function is equipped to perform in accordance with appropriate professional standards for internal auditors;<\/pee> 8.5.5. ensure the internal auditor has direct access to the Board and Committee Chair, providing independence from the Executive and accountability to the Committee;<\/pee> 8.5.6. carry out an annual assessment of the effectiveness of the internal audit function and as part of this assessment:<\/pee> 8.5.6.1 meet with the head of internal audit without the presence of management to discuss the effectiveness of the function;<\/pee> 8.5.6.2 review and assess the annual internal audit work plan;<\/pee> 8.5.6.3 receive a report on the results of the internal auditor\u2019s work;<\/pee> 8.5.6.4 determine whether it is satisfied that the quality, experience and expertise of internal audit is appropriate for the business; and<\/pee> 8.5.6.5 review the actions taken by management to implement the recommendations of internal audit and to support the effective working of the internal audit function.<\/pee> 8.5.7. monitor and assess the role and effectiveness of the Company\u2019s internal audit function in the overall context of the Company\u2019s risk management system and the work of compliance, finance and the external auditor; and<\/pee> 8.5.8. consider whether an independent, third party review of processes is appropriate.<\/pee> 8.6. External Audit<\/pee> The Committee shall:<\/pee> 8.6.1. consider and make recommendations to the Board, to be put to shareholders for approval at the AGM, in relation to the appointment, re\u2010appointment and removal of the Company\u2019s external auditor;<\/pee> 8.6.2. develop and oversee the selection procedure for the appointment of the audit firm in accordance with applicable Code and regulatory requirements, ensuring that all tendering firms have access to all necessary information and individuals during the tendering process;<\/pee> 8.6.3. if an external auditor resigns, investigate the issues leading to this and decide whether any action is required;<\/pee> 8.6.4. oversee the relationship with the external auditor. In this context the Committee shall:<\/pee> 8.6.4.1. approval of their remuneration, including both fees for audit or non\u2010 audit services and ensure that the level of fees is appropriate to enable an effective and high-quality audit to be conducted; and<\/pee> 8.6.4.2. approve their terms of engagement, including any engagement letter issued at the start of each audit and the scope of the audit.<\/pee> 8.6.5 assess annually the external auditor\u2019s independence and objectivity taking into account relevant law, regulation, the Ethical Standard and other professional requirements and the Group\u2019s relationship with the auditor as a whole, including any threats to the auditor\u2019s independence and the safeguards applied to mitigate those threats including the provision of any non\u2010audit services;<\/pee> 8.6.6 satisfy itself that there are no relationships between the auditor and the Company (other than in the ordinary course of business) which could adversely affect the auditor\u2019s independence and objectivity;<\/pee> 8.6.7 agree with the Board a policy on the employment of former employees of the Company\u2019s auditor, taking into account the Ethical Standard and legal requirements, then monitoring the implementation of this policy;<\/pee> 8.6.8 monitor the auditor\u2019s processes for maintaining independence, its compliance with relevant law, regulation, other professional requirements and the Ethical Standard, including the guidance on the rotation of audit partner and staff;<\/pee> 8.6.9 monitor the level of fees paid by the Company to the external auditor compared to the overall fee income of the firm, office and partner and assess these in the context of relevant legal, professional and regulatory requirements, guidance and the Ethical Standard;<\/pee> 8.6.10 assess annually the qualifications, expertise and resources, and independence and the effectiveness of the external audit process, which shall include a report from the external auditor on their own internal quality procedures;<\/pee> 8.6.11 seek to ensure co\u2010ordination with the activities of the internal audit function;<\/pee> 8.6.12 evaluate the risks to the quality and effectiveness of the financial reporting process in the light if the external auditor\u2019s communications with the Committee;<\/pee> 8.6.13 develop and recommend to the Board the Company\u2019s formal policy on the provision of non-audit services by the auditor, including prior approval of non-audit services by the Committee and specifying the types of non-audit service to be pre-approved, and assessment of whether non-audit services have a direct or material effect on the audited financial statements. The policy should include consideration of the following matters:<\/pee> 8.6.13.1 threats to the independence and objectivity of the external auditor and any safeguards in place;<\/pee> 8.6.13.2 the nature of the non\u2010audit services;<\/pee> 8.6.13.3 whether the external audit firm is the most suitable supplier of the non\u2010audit service;<\/pee> 8.6.13.4 the fees for the non\u2010audit services, both individually and in aggregate, relative to the audit fee; and<\/pee> 8.6.13.5 the criteria governing compensation.<\/pee> 8.6.14 meet regularly with the external auditor (including once at the planning stage before the audit and once after the audit at the reporting stage) and, at least once a year, meet with the external auditor without management being present, to discuss the auditor\u2019s remit and any issues arising from the audit;<\/pee> 8.6.15 discuss with the external auditor the factors that could affect audit quality and review and approve the annual audit plan and ensure that it is consistent with the scope of the audit engagement, having regard to the seniority, expertise and experience of the audit team;<\/pee> 8.6.16 review the findings of the audit with the external auditor. This shall include but not be limited to, the following:<\/pee> 8.6.16.1 a discussion of any major issues which arose during the audit;<\/pee> 8.6.16.2 the auditor\u2019s explanation of how the risks to audit quality were addressed;<\/pee> 8.6.16.3 any accounting and audit judgements;<\/pee> 8.6.16.4 the auditor\u2019s view of their interactions with senior management; and<\/pee> 8.6.16.5 levels of errors identified during the audit.<\/pee> 8.6.17 review of any representation letter(s) requested by the external auditor before they are signed by the management;<\/pee> 8.6.18 review of the management letter and management\u2019s response to the auditor\u2019s findings and recommendations; and<\/pee> 8.6.19 review the effectiveness of the audit process, including an assessment of the quality of the audit, the handling of key judgements by the auditor, and the auditor\u2019s response to questions from the Committee. <\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 9. Reporting Responsibilities<\/h5>\n
9.1 The Committee Chair shall report formally to the Board on its proceedings after each meeting on all matters within its duties and responsibilities and shall formally report to the Board on how it has discharged its responsibilities. This report shall include:<\/pee> 9.1.1 the significant issues that it considered in relation to the financial statements (required under paragraph 8.1.1) and how these were addressed;<\/pee> 9.1.2 its assessment of the effectiveness of the external audit process (required under paragraph 8.6.10), the approach taken to the appointment or reappointment of the external auditor, length of tenure of the audit firm, when a tender was last conducted and advance notice of any retendering plans; and<\/pee> 9.1.3 any other issues on which the Board has requested the Committee\u2019s opinion.<\/pee> 9.2 The Committee shall make whatever recommendations to the Board it deems appropriate on any area within its remit where action or improvement is needed.<\/pee> 9.3 The Committee shall compile a report on its activities to be included in the Company\u2019s Annual Report. The report should describe the work of the Committee, including:<\/pee> 9.3.1 the significant issues that the Committee considered in relation to the financial statements and how these issues were addressed;<\/pee> 9.3.2 an explanation of how the Committee has assessed the independence and effectiveness of the external audit process and the approach taken to the appointment or reappointment of the external auditor, information on the length of tenure of the current audit firm, when a tender was last conducted and advance notice of any retendering plans; and<\/pee> 9.3.3 an explanation of how auditor independence and objectivity are safeguarded if the external auditor provides non-audit services, having regard to matters communicated to it by the auditor and all other information requirements set out in the Code.<\/pee> 9.4 In compiling the reports referred to in 9.1 and 9.3, the Committee should exercise judgement in deciding which of the issues it considers in relation to the financial statements are significant, but should include at least those matters that have informed the Board\u2019s assessment of whether the Company is a going concern. The report to shareholders need not repeat information disclosed elsewhere in the Annual Report and accounts, but could provide cross\u2010references to that information.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 10. Other Matters<\/h5>\n
The Committee shall:<\/pee> 10.1 have access to sufficient resources in order to carry out its duties, including access to the company secretariat for assistance as required;<\/pee> 10.2 be provided with appropriate and timely training, both in the form of an induction programme for new members and on an ongoing basis for all members;<\/pee> 10.3 give due consideration to laws and regulations, the provisions of the 2018 UK Corporate Governance Code and published guidance, the requirements of the FCA\u2019s Listing Rules, Prospectus Rules and Disclosure Guidance and Transparency Rules sourcebook and any other applicable rules, as appropriate;<\/pee> 10.4 be responsible for oversight of the co\u2010ordination of the internal and external auditors;<\/pee> 10.5 oversee any investigation of activities which are within its terms of reference;<\/pee> 10.6 work and liaise as necessary with all other Board committees ensuring interaction between committees and with the Board is reviewed regularly, taking particular account of the impact of risk management and internal controls being delegated to different committees;<\/pee> 10.7 ensure that a periodic evaluation of the Committee\u2019s performance is carried out; and<\/pee> 10.8 at least annually, review its constitution and terms of reference to ensure it is operating at maximum effectiveness and recommend any changes it considers necessary to the Board for approval.<\/pee>[\/et_pb_code][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” custom_margin=”2rem||2rem||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”]<\/p>\n 11. Authority<\/h5>\n
The Committee is authorised to:<\/pee> 11.1. seek any information it requires from any employee of the Company in order to perform its duties;<\/pee> 11.2. obtain, at the Company\u2019s expense, independent legal, accounting or other professional advice on any matter if it believes it necessary to do so;<\/pee> 11.3. call any employee to be questioned at a meeting of the Committee as and when required; and<\/pee> 11.4. have the right to publish in the Company\u2019s Annual Report, details of any issues that cannot be resolved between the Committee and the Board. If the Board has not accepted the Committee\u2019s recommendation on the external auditor appointment, reappointment or removal, the Annual Report should include a statement explaining the Committee\u2019s recommendation and the reasons why the board has taken a different position.<\/pee>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"The Committee shall comprise at least two members all of whom shall be independent Non\u2010Executive Directors, at least one of whom shall have recent and relevant financial experience and the Committee as a whole shall have competence relevant in which the Company operates.<\/p>\n","protected":false},"author":4,"featured_media":800,"parent":115,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"page_collections":[],"class_list":["post-120","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n
Audit Committee - Advanced Medical Solutions<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Audit Committee\" \/>\n<meta property=\"og:description\" content=\"1.1. The Committee shall comprise at least two members all of whom shall be independent Non\u2010Executive Directors, at least one of whom shall have recent and relevant financial experience and the Committee as a whole shall have competence relevant in which the Company operates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/\" \/>\n<meta property=\"og:site_name\" content=\"Advanced Medical Solutions\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-19T11:14:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Audit-Comittee.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"18 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/\",\"url\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/\",\"name\":\"Audit Committee - Advanced Medical Solutions\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Audit-Comittee.jpg\",\"datePublished\":\"2022-09-13T11:51:28+00:00\",\"dateModified\":\"2024-02-19T11:14:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Audit-Comittee.jpg\",\"contentUrl\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Audit-Comittee.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/audit-committee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admedsol.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Relations\",\"item\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Corporate Governance\",\"item\":\"https:\\\/\\\/admedsol.com\\\/investor-relations\\\/corporate-governance\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Audit Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/#website\",\"url\":\"https:\\\/\\\/admedsol.com\\\/\",\"name\":\"Advanced Medical Solutions\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admedsol.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/#organization\",\"name\":\"Advanced Medical Solutions\",\"url\":\"https:\\\/\\\/admedsol.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admedsol.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ams-logo-on-white.webp\",\"contentUrl\":\"https:\\\/\\\/admedsol.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ams-logo-on-white.webp\",\"width\":1200,\"height\":845,\"caption\":\"Advanced Medical Solutions\"},\"image\":{\"@id\":\"https:\\\/\\\/admedsol.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/advanced-medical-solutions\\\/\",\"https:\\\/\\\/uk.linkedin.com\\\/showcase\\\/advanced-medical-solutions-surgical\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/showcase\\\/advanced-medical-solutions-woundcare\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Audit Committee - Advanced Medical Solutions","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/","og_locale":"en_US","og_type":"article","og_title":"Audit Committee","og_description":"1.1. The Committee shall comprise at least two members all of whom shall be independent Non\u2010Executive Directors, at least one of whom shall have recent and relevant financial experience and the Committee as a whole shall have competence relevant in which the Company operates.","og_url":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/","og_site_name":"Advanced Medical Solutions","article_modified_time":"2024-02-19T11:14:15+00:00","og_image":[{"url":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Audit-Comittee.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/","url":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/","name":"Audit Committee - Advanced Medical Solutions","isPartOf":{"@id":"https:\/\/admedsol.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/#primaryimage"},"image":{"@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Audit-Comittee.jpg","datePublished":"2022-09-13T11:51:28+00:00","dateModified":"2024-02-19T11:14:15+00:00","breadcrumb":{"@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/#primaryimage","url":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Audit-Comittee.jpg","contentUrl":"https:\/\/admedsol.com\/wp-content\/uploads\/2023\/06\/Audit-Comittee.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/audit-committee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admedsol.com\/"},{"@type":"ListItem","position":2,"name":"Investor Relations","item":"https:\/\/admedsol.com\/investor-relations\/"},{"@type":"ListItem","position":3,"name":"Corporate Governance","item":"https:\/\/admedsol.com\/investor-relations\/corporate-governance\/"},{"@type":"ListItem","position":4,"name":"Audit Committee"}]},{"@type":"WebSite","@id":"https:\/\/admedsol.com\/#website","url":"https:\/\/admedsol.com\/","name":"Advanced Medical Solutions","description":"","publisher":{"@id":"https:\/\/admedsol.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admedsol.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admedsol.com\/#organization","name":"Advanced Medical Solutions","url":"https:\/\/admedsol.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admedsol.com\/#\/schema\/logo\/image\/","url":"https:\/\/admedsol.com\/wp-content\/uploads\/2024\/01\/ams-logo-on-white.webp","contentUrl":"https:\/\/admedsol.com\/wp-content\/uploads\/2024\/01\/ams-logo-on-white.webp","width":1200,"height":845,"caption":"Advanced Medical Solutions"},"image":{"@id":"https:\/\/admedsol.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/advanced-medical-solutions\/","https:\/\/uk.linkedin.com\/showcase\/advanced-medical-solutions-surgical\/","https:\/\/www.linkedin.com\/showcase\/advanced-medical-solutions-woundcare\/"]}]}},"_links":{"self":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages\/120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/comments?post=120"}],"version-history":[{"count":0,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages\/120\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/pages\/115"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/media\/800"}],"wp:attachment":[{"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/media?parent=120"}],"wp:term":[{"taxonomy":"page_collections","embeddable":true,"href":"https:\/\/admedsol.com\/wp-json\/wp\/v2\/page_collections?post=120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}